"Chemokine CXCL12" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CXC chemokine that is chemotactic for T-LYMPHOCYTES and MONOCYTES. It has specificity for CXCR4 RECEPTORS. Two isoforms of CXCL12 are produced by alternative mRNA splicing.
| Descriptor ID |
D054377
|
| MeSH Number(s) |
D12.644.276.374.200.120.600 D12.776.467.374.200.120.600 D23.125.300.120.600 D23.469.200.120.600 D23.529.374.200.120.600
|
| Concept/Terms |
Chemokine CXCL12- Chemokine CXCL12
- CXCL12, Chemokine
- Stromal Cell-Derived Factor 1
- Stromal Cell Derived Factor 1
- CXCL12 Chemokine
- Chemokine, CXCL12
- Chemokine (C-X-C Motif) Ligand 12
- Pre-B-Cell Growth-Stimulating Factor
- Growth-Stimulating Factor, Pre-B-Cell
- Pre B Cell Growth Stimulating Factor
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CXCL12".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CXCL12".
This graph shows the total number of publications written about "Chemokine CXCL12" by people in this website by year, and whether "Chemokine CXCL12" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemokine CXCL12" by people in Profiles.
-
Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism. Cell Rep. 2024 May 28; 43(5):114245.
-
IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis. PLoS One. 2015; 10(3):e0122439.
-
PPARa regulates mobilization and homing of endothelial progenitor cells through the HIF-1a/SDF-1 pathway. Invest Ophthalmol Vis Sci. 2014 May 20; 55(6):3820-32.